Cantor Fitzgerald analyst Pete Stavopoulos initiated coverage of Vera Therapeutics with an Overweight rating and no price target. The firm views Vera as attractive, as data from the Phase 2b ORIGIN study of ataci’ in IgAN were positive, clinically meaningful, and de-risking of the ongoing Phase 3 ORIGIN-3 study, supporting its high conviction for a positive Phase 3 readout in 1H25, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Best Stock to Buy Today, 12/28/2023, According to Top Analysts
- H.C. Wainwright estimates Vera’s cash runway now extends into Q2 2026
- Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Vera Therapeutics initiated with an Outperform at Raymond James
- Vera Therapeutics price target lowered to $22 from $25 at JPMorgan